The inhibition of the IL-1β pathway by Anakinra, an antagonist of the IL-1R1 or through the monoclonal IL1RAP antibody mAb81.2, attenuated the expansion of CML LSCs [134]. This evidence concerns the gene IL1R1 and chronic myelogenous leukemia, BCR-ABL1 positive.